Chimerism genetic testing is used to monitor the success of haemopoietic stem cell transplantation (HSCT) by evaluating the ratio of donor and recipient DNA in the recipient's blood or bone marrow.
This guides treatment to help prevent engraftment failure, to maximise graft-versus-tumour effect and to minimise opportunistic infection and graft-versus-host disease.
Flow sorted chimerism analysis of peripheral blood can be used to monitor T-cell, B-cell and myeloid lineage specific engraftment upon request.
New referrals require a genotyping workup. This requires pre-transplant samples from both recipient and donor.